キャンディン系抗真菌薬

[Wikipedia|▼Menu]

□記事を途中から表示しています
[最初から表示]

^ “Fungal beta(1,3)-D-glucan synthesis”. Medical Mycology 39 (Suppl 1): 55?66. (2001). doi:10.1080/mmy.39.1.55.66. PMID 11800269.
^ “Membrane and cell wall targets in Aspergillus fumigatus”. Drug Resistance Updates 4 (1): 38?49. (February 2001). doi:10.1054/drup.2001.0185. PMID 11512152.
^ “A drug-sensitive genetic network masks fungi from the immune system”. PLOS Pathogens 2 (4): e35. (April 2006). doi:10.1371/journal.ppat.0020035. PMC 1447670. PMID 16652171. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1447670/.
^ Perlin, DS (1 December 2015). “Echinocandin Resistance in Candida.”. Clinical Infectious Diseases 61 (Suppl 6): S612-7. doi:10.1093/cid/civ791. PMC 4643482. PMID 26567278. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643482/.
^ Wagener, Johannes; Loiko, Veronika (28 December 2017). “Recent Insights into the Paradoxical Effect of Echinocandins”. Journal of Fungi 4 (1): 5. doi:10.3390/jof4010005. PMC 5872308. PMID 29371498. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872308/.
^ Chandrasekar, P H (24 January 2007). “Increased dose of echinocandins for invasive fungal infections: bonanza for the patient or the pharmaceutical industry?”. Bone Marrow Transplantation 39 (3): 129?131. doi:10.1038/sj.bmt.1705563. PMID 17245422.
^ Eschenauer, Gregory; DePestel, Daryl D; Carver, Peggy L (February 2007). “Comparison of echinocandin antifungals”. Therapeutics and Clinical Risk Management 3 (1): 71?97. doi:10.2147/tcrm.2007.3.1.71. PMC 1936290. PMID 18360617. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936290/.
^ Ashley, Elizabeth S. Dodds; Lewis, Russell; Lewis, James S.; Martin, Craig; Andes, David (2006-08-01). ⇒“Pharmacology of Systemic Antifungal Agents” (英語). Clinical Infectious Diseases 43 (Supplement_1): S28?S39. doi:10.1086/504492. ISSN 1537-6591. ⇒http://academic.oup.com/cid/article/43/Supplement_1/S28/318707/Pharmacology-of-Systemic-Antifungal-Agents.
^ “Newer systemic antifungal agents : pharmacokinetics, safety and efficacy”. Drugs 64 (18): 1997?2020. (2004). doi:10.2165/00003495-200464180-00001. PMID 15341494. https://zenodo.org/record/1236417.
^ “Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients”. Pediatric Blood & Cancer 55 (2): 229?32. (August 2010). doi:10.1002/pbc.22449. PMID 20583216.
^ Diagnosis and Treatment of Fungal Infections. Springer. (2015-05-12). p. 95. ISBN 978-3-319-13090-3
^ “Comparison of echinocandin antifungals”. Therapeutics and Clinical Risk Management 3 (1): 71?97. (March 2007). doi:10.2147/tcrm.2007.3.1.71. PMC 1936290. PMID 18360617. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936290/.
^ Thompson, George R.; Soriano, Alex; Skoutelis, Athanasios; Vazquez, Jose A.; Honore, Patrick M.; Horcajada, Juan P.; Spapen, Herbert; Bassetti, Matteo et al. (2021-12-06). “Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial”. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 73 (11): e3647?e3655. doi:10.1093/cid/ciaa1380. ISSN 1537-6591. PMC 8662762. PMID 32955088. https://pubmed.ncbi.nlm.nih.gov/32955088.
^ Huttel, Wolfgang (2021-01). “Echinocandins: structural diversity, biosynthesis, and development of antimycotics”. Applied Microbiology and Biotechnology 105 (1): 55?66. doi:10.1007/s00253-020-11022-y. ISSN 1432-0614. PMC 7778625. PMID 33270153. https://pubmed.ncbi.nlm.nih.gov/33270153.
^ Szyma?ski, Mateusz; Chmielewska, Sandra; Czy?ewska, Urszula; Malinowska, Marta; Tylicki, Adam (2022-12). “Echinocandins - structure, mechanism of action and use in antifungal therapy”. Journal of Enzyme Inhibition and Medicinal Chemistry 37 (1): 876?894. doi:10.1080/14756366.2022.2050224. ISSN 1475-6374. PMC 8933026. PMID 35296203. https://pubmed.ncbi.nlm.nih.gov/35296203.

次ページ

記事の検索

Size:33 KB
出典: フリー百科事典『ウィキペディア（Wikipedia）』
担当:undef